Physician profile
Mary Beckwith
NPI 1508848508
$981.62
in general payments reported to CMS, 2019-2025
18 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.30 · 2020: $18.59 · 2022: $342 · 2023: $219 · 2024: $111 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.22 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Mayne Pharma Commercial LLC | $140.17 | 2022-2024 | |
| Astellas Pharma US INC | $92.51 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $80.15 | 2019-2025 | |
| Biogen, INC. | $73.95 | 2025 | Zurzuvae |
| Coopersurgical, INC. | $61.66 | 2022-2023 | Paragard T 380a |
| Hologic Sales and Service, LLC | $54.06 | 2023-2025 | Novasure, Acessa Provu System, Aptima |
| Pfizer INC. | $49.24 | 2022-2023 | |
| Axsome Therapeutics, INC. | $21.02 | 2024 | Auvelity |
| Organon LLC | $19.96 | 2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $17.27 | 2023 | Myfembree |
| Avanos Medical | $16.43 | 2023 | On-Q* Pump and Accessories |
| Exeltis, USA INC. | $15.10 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2023 | Seglentis |
| Therapeuticsmd, INC. | $14.54 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $14.44 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Myovant Sciences INC. | $14.20 | 2022 | |
| Shield Therapeutics INC | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beckwith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.